Siolta Therapeutics’ mission is to develop next-generation microbial therapeutics aimed at the prevention and treatment of inflammatory diseases. Its unique and multifaceted platform utilizes an ecosystems approach for patient stratification, immunomodulatory assessment, and rationally designed microbial consortia in order to provide efficacious live biotherapeutics. Current efforts focus on the prevention and treatment of allergic disease, including allergic asthma, using a proprietary mixed-species (or “next-generation”) microbial therapeutic. This licensed platform technology also allows Siolta to develop similar therapeutics for a myriad of inflammatory diseases, in its pursuit of holistic healthcare focused on microbiome-based strategies for patient stratification and tailored, clinically differentiated microbial therapeutics.
Working towards a healthier world for future generations.
Co-founded in late 2016 by Susan Lynch (University of California at San Francisco, or UCSF), Samir Kaul (Khosla Ventures), and Nikole Kimes (Siolta, formerly UCSF), Siolta blends expertise from the venture-backed start-up world with the scientific background and know-how to realize its vision in a streamlined manner. Since Siolta’s inception, they have built an exceptional team and moved rapidly through translation development towards clinical trials, advancing our scientific and regulatory goals along the way.